PT2525796T - Solução aquosa incluindo 3-quinuclidinonas para o tratamento de doenças hiperproliferativas, auto-imunes e cardíacas - Google Patents

Solução aquosa incluindo 3-quinuclidinonas para o tratamento de doenças hiperproliferativas, auto-imunes e cardíacas

Info

Publication number
PT2525796T
PT2525796T PT117013920T PT11701392T PT2525796T PT 2525796 T PT2525796 T PT 2525796T PT 117013920 T PT117013920 T PT 117013920T PT 11701392 T PT11701392 T PT 11701392T PT 2525796 T PT2525796 T PT 2525796T
Authority
PT
Portugal
Prior art keywords
quinuclidinones
aquosa
hyperproliferative
immune
self
Prior art date
Application number
PT117013920T
Other languages
English (en)
Portuguese (pt)
Inventor
Byström Styrbjörn
Liljebris Charlotta
Caram-Lelham Cninus
Original Assignee
Aprea Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprea Ab filed Critical Aprea Ab
Publication of PT2525796T publication Critical patent/PT2525796T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT117013920T 2010-01-21 2011-01-21 Solução aquosa incluindo 3-quinuclidinonas para o tratamento de doenças hiperproliferativas, auto-imunes e cardíacas PT2525796T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29696410P 2010-01-21 2010-01-21
EP10151326 2010-01-21

Publications (1)

Publication Number Publication Date
PT2525796T true PT2525796T (pt) 2016-07-11

Family

ID=42212171

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117013920T PT2525796T (pt) 2010-01-21 2011-01-21 Solução aquosa incluindo 3-quinuclidinonas para o tratamento de doenças hiperproliferativas, auto-imunes e cardíacas

Country Status (22)

Country Link
US (1) US9061016B2 (enEXAMPLES)
EP (1) EP2525796B1 (enEXAMPLES)
JP (2) JP5845193B2 (enEXAMPLES)
KR (1) KR101727085B1 (enEXAMPLES)
CN (2) CN102781447B (enEXAMPLES)
AU (1) AU2011208681B2 (enEXAMPLES)
BR (1) BR112012017994B8 (enEXAMPLES)
CA (1) CA2786824C (enEXAMPLES)
CY (1) CY1117659T1 (enEXAMPLES)
DK (1) DK2525796T3 (enEXAMPLES)
ES (1) ES2578513T3 (enEXAMPLES)
HU (1) HUE028285T2 (enEXAMPLES)
IL (1) IL220318A (enEXAMPLES)
IN (1) IN2012DN05192A (enEXAMPLES)
PH (1) PH12012501402A1 (enEXAMPLES)
PL (1) PL2525796T3 (enEXAMPLES)
PT (1) PT2525796T (enEXAMPLES)
RU (1) RU2571566C2 (enEXAMPLES)
SG (1) SG182537A1 (enEXAMPLES)
SM (1) SMT201600189B (enEXAMPLES)
WO (1) WO2011089234A2 (enEXAMPLES)
ZA (1) ZA201204424B (enEXAMPLES)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5845193B2 (ja) * 2010-01-21 2016-01-20 アプレア エイビー 過増殖性疾患、自己免疫疾患、および心疾患の治療のための3−キヌクリジノンを含有する水溶液
CN104860994A (zh) * 2014-02-20 2015-08-26 中国药科大学 3-奎宁环酮类含磷化合物的制备及其医药用途
CN109280056A (zh) * 2017-07-21 2019-01-29 上海时莱生物技术有限公司 手性3-奎宁环酮类化合物、制备方法及用途
EP3762035A4 (en) * 2018-03-09 2022-03-02 Texas Tech University System COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER IN ALT
US20220087987A1 (en) * 2018-12-27 2022-03-24 National Cancer Center A method for treating swi/snf complex-deficient cancers comprising glutathione (gsh) metabolic pathway inhibitor
AU2020349041A1 (en) 2019-09-18 2022-04-28 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic Bcl-2 family protein
CN116034107A (zh) * 2020-02-09 2023-04-28 新波制药有限公司 用作抗癌剂的奎宁环酮类似物
CN111257458B (zh) * 2020-02-20 2022-07-22 北京鑫开元医药科技有限公司海南分公司 一种3-奎宁环酮盐酸盐的检测方法及应用
WO2021170772A1 (en) 2020-02-26 2021-09-02 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling
WO2021180338A1 (en) 2020-03-09 2021-09-16 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of dna methyltransferase post stem cell transplant

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3775418A (en) * 1970-07-15 1973-11-27 American Home Prod 3-((3-azaspiro(5,5)undecino)methyl)-3-quinuclidinol
ATE413176T1 (de) * 2000-09-20 2008-11-15 Aprea Ab Verwendung von 1-azabicyclo(2.2.2)octan-3-on- derivaten zur behandlung von krebstumoren
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
RU2226288C2 (ru) 2001-07-10 2004-03-27 ОПТИВА, Инк. Многослойное оптическое покрытие
CA2476825C (en) * 2002-02-21 2011-04-05 Aprea Ab Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
AU2004224488B2 (en) 2003-03-24 2009-09-10 Aprea Therapeutics Ab Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53
SE0400708D0 (sv) 2004-03-22 2004-03-22 Aprea Ab New compounds and use thereof
JP2007269786A (ja) * 2006-03-09 2007-10-18 Daiichi Sankyo Healthcare Co Ltd パンテチン含有経口液剤
JP2008001606A (ja) * 2006-06-20 2008-01-10 Mitsubishi Pharma Corp ピラゾロン化合物を含有する水溶液剤
RU2419421C2 (ru) * 2006-07-18 2011-05-27 Хенфарма Лабораторио С.Л. Инъецируемая жидкая композиция парацетамола
JP2008201778A (ja) 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
UA101950C2 (ru) * 2007-03-01 2013-05-27 Новартис Аг Соль присоединения с кислотами, гидрат и полиморфная форма этиламида 5-(2,4-дигидрокси-5-изопропилфенил)-4-(4-морфолин-4-илметилфенил)-изоксазол-3-карбоновой кислоты и композиция, которая содержит эти формы (варианты)
JP5845193B2 (ja) * 2010-01-21 2016-01-20 アプレア エイビー 過増殖性疾患、自己免疫疾患、および心疾患の治療のための3−キヌクリジノンを含有する水溶液

Also Published As

Publication number Publication date
RU2571566C2 (ru) 2015-12-20
JP5845193B2 (ja) 2016-01-20
IL220318A (en) 2015-10-29
JP2013518036A (ja) 2013-05-20
AU2011208681A1 (en) 2012-07-05
US20120289503A1 (en) 2012-11-15
AU2011208681B2 (en) 2014-10-23
RU2012135698A (ru) 2014-02-27
PH12012501402A1 (en) 2016-07-27
BR112012017994A2 (pt) 2016-05-03
SG182537A1 (en) 2012-08-30
BR112012017994B8 (pt) 2020-12-08
HUE028285T2 (en) 2016-12-28
CA2786824C (en) 2018-04-10
ZA201204424B (en) 2013-08-28
AU2011208681A8 (en) 2013-01-31
DK2525796T3 (en) 2016-07-04
EP2525796B1 (en) 2016-03-30
US9061016B2 (en) 2015-06-23
BR112012017994B1 (pt) 2020-01-14
ES2578513T3 (es) 2016-07-27
SMT201600189B (it) 2016-08-31
CA2786824A1 (en) 2011-07-28
WO2011089234A8 (en) 2012-09-07
KR101727085B1 (ko) 2017-04-14
CN106963759A (zh) 2017-07-21
CY1117659T1 (el) 2017-05-17
CN106963759B (zh) 2020-07-07
JP6106228B2 (ja) 2017-03-29
CN102781447B (zh) 2016-11-23
WO2011089234A2 (en) 2011-07-28
PL2525796T3 (pl) 2016-09-30
CN102781447A (zh) 2012-11-14
JP2016020356A (ja) 2016-02-04
WO2011089234A3 (en) 2011-10-06
KR20120123441A (ko) 2012-11-08
IN2012DN05192A (enEXAMPLES) 2015-10-23
EP2525796A2 (en) 2012-11-28

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
PT2525796T (pt) Solução aquosa incluindo 3-quinuclidinonas para o tratamento de doenças hiperproliferativas, auto-imunes e cardíacas
CO7061081A2 (es) Derivados macrocíclicos para el tratamiento de enfermedades
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
CO6910184A2 (es) Nuevos compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide
HUE039864T2 (hu) Gyógyászati készítmények CFTR-közvetítette betegségek kezelésére
EP2641614A4 (en) INTEGRATED PHARMACEUTICAL PREPARATION WITH MICRO NEEDLES FOR SKIN TREATMENT
ZA201301601B (en) Treatment of diseases
HUE045367T2 (hu) Kombinált terápia diabétesz kezelésére
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
PT2582366E (pt) Combinação terapêutica para o tratamento da dor
PT2632300T (pt) Almofada cervical para o tratamento de doenças da coluna cervical
HUE054196T2 (hu) Terápiás szerek nemkívánatos sejtproliferációhoz kapcsolódó betegségek kezelésére
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
SG11201503231YA (en) METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES
LTPA2020511I1 (lt) Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
IL234606A0 (en) Novel methods and composition for treatment of disease
HRP20190169T1 (hr) Postupci liječenja povećanja tjelesne težine inducirane antipsihoticima
SG11201404649UA (en) Novel compounds for the treatment of dyslipidemia and related diseases
ES2590358T8 (es) Dispositivos intravasculares para el tratamiento de vasos sanguíneos
BR112013004683A2 (pt) "conjunto de cateter para tratamento de nervo"
PL392436A1 (pl) Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
LT2531124T (lt) Prietaisai odos pažeidimams gydyti